A Phase 1/2 interventional study of End-expiratory lung volume optimization maneuver with PEEP titration and Standard Care (in control arm) in Congenital Heart Disease, Cardiopulmonary Bypass and Mechanical Ventilation, sponsored by Charite University, Berlin, Germany. Not yet recruiting at 1 site in Germany. Open to participants aged 0 Days to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Charite University, Berlin, Germany · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Heart Defects, Congenital with a site in Germany — 15 open to participants now, 15 under way, none of them phase 3. Heart Defects, Congenital · Germany.
Among the 38 studies in Heart Defects, Congenital with a site in Germany, this one is the 9th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2027, is one of 2 in phase 1/2, reaches primary completion later than 9 of the 14 other live ones, and was the 36th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →15 of the 38 studies in Heart Defects, Congenital with a site in Germany are open now. Recruiting first, the newest first:
Alexandra Miriam Kiess · Sites in Germany
Ages 6–18
University Hospital Tuebingen · Sites in Germany
Charite University, Berlin, Germany · Sites in Germany
Ages 0–18
Fondation Hôpital Saint-Joseph · Sites in Germany, Denmark, Egypt and 14 more countries
Ages 1 mo+
Deutsches Herzzentrum Muenchen · Sites in Germany
Ages 8–14
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 0 Days to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4 · Phase 4 1
First in 2003; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 70 across the 24 interventional studies, 300 across the 14 observational. Of the 19 that completed or were terminated, 4 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 38 have an industry lead sponsor. The 10 most frequent:
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
Charite University, Berlin, Germany has 5 studies filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
4 of the studies in Heart Defects, Congenital with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823635Fondation Hôpital Saint-JosephAn International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects | 2026-12-31 |
| NCT07716488Alexandra Miriam KiessScreening for Disorders of Lipid Metabolism and Familial Hyperlipidemia in Children and Adolescents With Increased Cardiovascular Risk Due to Chronic Diseases Such as Congenital Heart Disease, Chronic Inflammatory Bowel Disease, Celiac Disease and Rheumatic Disorders | 2027-01-31 |
| NCT06845371University Hospital TuebingenMELODY Registry Follow-Up Study | 2027-05-01 |
| NCT07193719Charite University, Berlin, GermanyInfluence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies in Heart Defects, Congenital with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this randomized interventional multi-center clinical trial is to determine whether a standardized lung volume optimization maneuver (LVOM), including PEEP titration, improves outcomes in children undergoing biventricular repair for congenital heart disease (CHD) with cardiopulmonary bypass.
The primary hypothesis is that optimizing end-expiratory lung volume through a standardized PEEP titration maneuver improves cardiac performance and lung function.
Secondary objectives are to evaluate whether this strategy reduces duration of mechanical ventilation, improves hemodynamics and ventilation-perfusion matching, and decreases the need for vasopressor support.
Cardiopulmonary bypass is associated with interruption of ventilation, leading to atelectasis, reduced end-expiratory lung volume, and increased pulmonary vascular resistance (PVR), which may impair right ventricular (RV) performance and overall cardiac output.
This study investigates whether a structured LVOM strategy can mitigate these effects by improving lung mechanics and cardiopulmonary interactions.
Specific Aims
Aim 1:
To quantify changes in hemodynamics and lung mechanics induced by LVOM under standardized postoperative (closed-chest) conditions.
Aim 2:
To compare individualized PEEP titration versus standard ventilation in terms of effects on hemodynamics and lung mechanics, while maintaining consistent tidal volume targets across groups.
Hypotheses
LVOM will improve lung mechanics and hemodynamic parameters. No significant between-group differences are expected prior to intervention. After PEEP titration, the intervention group will demonstrate superior cardiopulmonary function at moderate PEEP levels, reflecting the U-shaped relationship between lung volume and pulmonary vascular resistance (PVR).
Scientific Rationale
Cardiopulmonary bypass commonly results in atelectasis and loss of end-expiratory lung volume, contributing to increased PVR and RV afterload, with subsequent reduction in cardiac output.
Adult studies suggest that lung volume optimization through PEEP titration after CPB can improve cardiac index and RV performance. However, prospective pediatric data evaluating the interaction between ventilatory strategy, lung mechanics, and hemodynamics remain limited.
Given the central role of the right ventricle in coupling pulmonary and systemic circulation, optimizing lung volume may reduce RV afterload and improve overall cardiac performance.
Importantly, pulmonary vascular resistance follows a U-shaped relationship with lung volume, with increased resistance at both low (atelectasis) and high (overdistension) lung volumes. Individualized PEEP titration may therefore identify an optimal range that minimizes PVR while preserving hemodynamic stability.
This study addresses a critical gap by systematically evaluating cardiopulmonary interactions under contemporary ventilation strategies in pediatric cardiac surgery.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group receives so called standard of care. This includes relatively low levels of PEEP (5cmH2O in case of planned surgery) and no standardized PEEP titration.
Procedure: Standard Care (in control arm)
This group receives an individual lung volume optimization maneuver with PEEP titration. PEEP titration is performed while monitoring lung mechanics and EIT indices of overdistension and collapse and regional tidal volume distribution to optimize end-expiratory lung volume and find final "best PEEP". If possible lung perfusion will be assessed with EIT to evaluate V/Q-matching.
Procedure: End-expiratory lung volume optimization maneuver with PEEP titration
PEEP titration (incremental/decremental) will be performed at the end of surgery to optimize lung volume and find levels of PEEP corresponding to the "best" lung compliance and "best" compromise of overdistension and collapse and "best" homogenization of tidal volume distribution assessed with EIT. PEEP levels will be applied based on individual response of patients' lung mechanics and EIT measures. Tidal volume will be kept constant at 6ml/kg in cases and controls. Driving pressures will be limited to 15cmH2O. Balance of CO2 will be guaranteed by adjusting respiratory rate.
Patients will receive pressure controlled ventilation with target tidal volume of 6ml/kg and PEEP of 5cmH2O. Driving pressures are limited to 15cmH2O. No LVOM will be applied.
Cardiac Index (L/min/BSA)
assessed by using POCUS
Time frame: perioperatively
lung mechanics
lung compliance (ml/cmH2O/kg)
Time frame: perioperatively
right ventricular performance
TAPSE PAAT Strain
Time frame: perioperatively
ventilation distribution
EIT
Time frame: perioperatively
lung perfurision
EIT
Time frame: perioperatively
dead space fraction
pulmonary dead-space fraction (Vd/Vt)
Time frame: perioperatively
avDO2
difference in arteriovenous oxygen content
Time frame: perioperatively
Plan to share: Undecided
Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Sep 2026 → Jan 2027, primary completion Aug 2028 → Dec 2028 and completion Dec 2028 → Jun 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany →